Conflicts of interest may inhibit decision-making. This highlights problems that regulators and manufacturers face when serious reactions are discovered, with difficulties in deciding which of several consequent actions to take: to add specific warnings (cautions) or contraindications to the product label to issue a Direct Healthcare Professional Communication to allow informed patients to decide whether they will take the drug or, in the most serious cases, to withdraw the product or revoke the licence. However, the speed with which products have subsequently been withdrawn as a result of the discovery of serious adverse reactions has not consistently changed.
One index of its success is the increasing speed with which serious adverse drug reactions are discovered after marketing of a medicinal product.
Modern pharmacovigilance began in the 1960s, since when the subject has grown markedly, interest having particularly increased since 2010.
0 kommentar(er)
